Merck pays $6.7B for Terns Pharmaceuticals and its CMLcandidate TERN-701 as the Keytruda patent cliff nears. FDA approves Denali's Avlayah — the first biologic designed to cross the blood-brain barrier — for Hunter syndrome, and Corcept's Lifyorli (relacorilant) for platinum-resistantovarian cancer. Plus Ionis cuts Tryngolza's price 93%.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Merck, Terns Pharmaceuticals, TERN-701, chronic myeloid leukemia, CML, Keytruda, Denali Therapeutics, Avlayah, Hunter syndrome, MPS II, Corcept Therapeutics, Lifyorli,relacorilant, ovarian cancer, Ionis, Tryngolza, Beam Therapeutics, BEAM-302,Biogen, Alteogen, Novartis, Scemblix, Eli Lilly, Lilly, Novo Nordisk, Takeda
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →